Healthcare provider profile · identity verified

Stephen C Wissink, MD

Internal Medicine · LA CROSSE, WI · NPI 1114921863

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	785	207
Amlodipine Besylate	Amlodipine Besylate	476	135
Lisinopril	Lisinopril	456	124
Rosuvastatin Calcium	Rosuvastatin Calcium	388	112
Losartan Potassium	Losartan Potassium	365	106
Metoprolol Succinate	Metoprolol Succinate	293	83
Omeprazole	Omeprazole	291	76
Eliquis	Apixaban	285	57
Tamsulosin Hcl	Tamsulosin Hcl	272	73
Levothyroxine Sodium	Levothyroxine Sodium	261	70
Metoprolol Tartrate	Metoprolol Tartrate	246	66
Pravastatin Sodium	Pravastatin Sodium	210	59
Hydrochlorothiazide	Hydrochlorothiazide	188	55
Simvastatin	Simvastatin	172	48
Gabapentin	Gabapentin	170	40
Allopurinol	Allopurinol	155	37
Furosemide	Furosemide	142	49
Terazosin Hcl	Terazosin Hcl	128	30
Metformin Hcl Er	Metformin Hcl	117	36
Fluticasone Propionate	Fluticasone Propionate	112	43
Escitalopram Oxalate	Escitalopram Oxalate	103	25
Metformin Hcl	Metformin Hcl	101	29
Pantoprazole Sodium	Pantoprazole Sodium	98	26
Tramadol Hcl	Tramadol Hcl	97	25
Warfarin Sodium	Warfarin Sodium	92	19
Potassium Chloride	Potassium Chloride	87	28
Finasteride	Finasteride	83	21
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	80	22
Albuterol Sulfate Hfa	Albuterol Sulfate	79	39
Sertraline Hcl	Sertraline Hcl	77	23
Nitroglycerin	Nitroglycerin	71	59
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	68	19
Trulicity	Dulaglutide	62	12
Famotidine	Famotidine	61	21
Memantine Hcl	Memantine Hcl	58	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	57	15
Spironolactone	Spironolactone	57	12
Doxazosin Mesylate	Doxazosin Mesylate	55	12
Alendronate Sodium	Alendronate Sodium	54	13
Clopidogrel	Clopidogrel Bisulfate	54	17
Jardiance	Empagliflozin	50	13
Oxybutynin Chloride Er	Oxybutynin Chloride	50	11
Zolpidem Tartrate	Zolpidem Tartrate	50	suppressed
Bupropion Hcl Sr	Bupropion Hcl	48	11
Fluoxetine Hcl	Fluoxetine Hcl	48	13
Prednisone	Prednisone	47	21
Lovastatin	Lovastatin	45	12
Duloxetine Hcl	Duloxetine Hcl	43	suppressed
Ezetimibe	Ezetimibe	43	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	43	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	43	13
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	40	15
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	40	suppressed
Pregabalin	Pregabalin	40	suppressed
Ramipril	Ramipril	39	suppressed
Atenolol	Atenolol	37	12
Citalopram Hbr	Citalopram Hydrobromide	37	suppressed
Glimepiride	Glimepiride	37	12
Glipizide Er	Glipizide	37	11
Montelukast Sodium	Montelukast Sodium	36	13
Sumatriptan Succinate	Sumatriptan Succinate	36	suppressed
Mirtazapine	Mirtazapine	35	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	34	suppressed
Chlorthalidone	Chlorthalidone	34	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	33	12
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	suppressed
Clonazepam	Clonazepam	28	suppressed
Valsartan	Valsartan	28	suppressed
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	24	suppressed
Colchicine	Colchicine	23	suppressed
Farxiga	Dapagliflozin Propanediol	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Amoxicillin	Amoxicillin	21	12
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Incruse Ellipta	Umeclidinium Bromide	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	20	16
Alprazolam	Alprazolam	19	suppressed
Calcitriol	Calcitriol	19	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	19	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	18	suppressed
Nifedipine Er	Nifedipine	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Rybelsus	Semaglutide	18	suppressed
Xarelto	Rivaroxaban	18	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Diazepam	Diazepam	17	suppressed
Hydralazine Hcl	Hydralazine Hcl	17	suppressed
Klor-Con M20	Potassium Chloride	17	suppressed
Benazepril Hcl	Benazepril Hcl	16	suppressed
Celecoxib	Celecoxib	16	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	16	suppressed
Azelastine Hcl	Azelastine Hcl	15	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	15	suppressed
Glipizide	Glipizide	15	suppressed
Propranolol Hcl Er	Propranolol Hcl	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Metronidazole	Metronidazole	14	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	14	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Semglee (Yfgn) Pen	Insulin Glargine-Yfgn	13	suppressed
Trazodone Hcl	Trazodone Hcl	13	suppressed
Bumetanide	Bumetanide	12	suppressed
Carvedilol	Carvedilol	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Tadalafil	Tadalafil	12	suppressed
Tizanidine Hcl	Tizanidine Hcl	12	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	11	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Enalapril Maleate	Enalapril Maleate	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed
Nystatin	Nystatin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error